Published in Eur J Nucl Med Mol Imaging on August 01, 2010
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res (2012) 1.07
Imaging of angiogenesis: from morphology to molecules and from bench to bedside. Eur J Nucl Med Mol Imaging (2010) 1.01
Functional magnetic resonance imaging in oncology: state of the art. Radiol Bras (2015) 1.00
Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J (2013) 0.96
Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer (2012) 0.93
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol (2012) 0.93
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res (2014) 0.92
Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Invest New Drugs (2013) 0.87
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther (2011) 0.87
Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging. Angiogenesis (2011) 0.84
Oncologic Angiogenesis Imaging in the clinic---how and why. Imaging Med (2011) 0.80
GPU-accelerated compartmental modeling analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. PLoS One (2015) 0.77
KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model. PLoS One (2013) 0.77
Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model. Transl Oncol (2013) 0.77
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment. Oncotarget (2015) 0.76
Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response? Br J Radiol (2016) 0.75
The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. Front Pharmacol (2016) 0.75
Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice. Cancers (Basel) (2011) 0.75
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging (1997) 6.77
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
We should desist using RECIST, at least in GIST. J Clin Oncol (2007) 4.51
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med (2000) 2.75
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR (1984) 2.30
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res (2002) 2.05
Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol (2008) 2.03
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol (2003) 1.90
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol (2003) 1.88
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol (2005) 1.86
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol (2008) 1.74
Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med (2002) 1.71
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res (2005) 1.66
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res (2004) 1.58
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther (2008) 1.58
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging (2004) 1.54
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst (2002) 1.52
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 1.47
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer (2005) 1.42
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2003) 1.33
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res (2006) 1.27
Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol (2004) 1.26
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology (2007) 1.24
Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res (2005) 1.21
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol (2002) 1.18
Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res (2005) 1.12
A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs (2004) 1.12
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res (2009) 1.10
Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol (2003) 1.08
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer (2005) 1.07
Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Phys Med Biol (2006) 1.05
Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med (2007) 1.05
Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging (2004) 1.02
A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res (2009) 0.94
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol (2009) 0.93
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs (2008) 0.92
Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology (2009) 0.91
Functional imaging in phase I studies: decorations or decision making? J Clin Oncol (2003) 0.90
Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging (2007) 0.89
Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol (2008) 0.86
Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer (2005) 0.85
Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo. Magn Reson Med (2002) 0.84
Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer (2003) 0.83
Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol (2007) 0.81
The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med (2003) 0.80
Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging. Neurosurgery (2006) 0.78
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed (2002) 2.24
Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol (2008) 2.03
Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2008) 1.95
Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology (2006) 1.91
Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed (2002) 1.80
Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys (2010) 1.64
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol (2009) 1.52
Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag (2004) 1.51
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 1.47
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res (2012) 1.42
Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol (2007) 1.41
CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol (2013) 1.34
Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging (2012) 1.33
Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review. Radiographics (2009) 1.25
Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review. Skeletal Radiol (2011) 1.21
Bayesian methods for pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans Med Imaging (2006) 1.20
Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol (2006) 1.19
Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol (2012) 1.19
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging (2012) 1.18
Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology (2011) 1.12
Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics (2006) 1.12
Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J Natl Cancer Inst Monogr (2011) 1.12
Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. AJR Am J Roentgenol (2007) 1.08
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Novel oncologic drugs: what they do and how they affect images. Radiographics (2011) 1.05
Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.04
Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech (2009) 1.03
Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI. J Magn Reson Imaging (2006) 1.02
Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging (2010) 0.98
Imaging tumour angiogenesis. Cancer Imaging (2005) 0.96
Dynamic optical breast imaging: a novel technique to detect and characterize tumor vessels. Eur J Radiol (2008) 0.96
Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys (2007) 0.95
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology (2010) 0.94
A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res (2009) 0.94
The role of functional imaging in colorectal cancer. AJR Am J Roentgenol (2010) 0.93
Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol (2011) 0.90
Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys (2010) 0.90
Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging (2007) 0.89
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res (2012) 0.89
Functional imaging of colorectal cancer angiogenesis. Lancet Oncol (2007) 0.87
A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study. Magn Reson Med (2009) 0.87
Coupled modeling of blood perfusion in intravascular, interstitial spaces in tumor microvasculature. J Biomech (2008) 0.87
A test of performance of breast MRI interpretation in a multicentre screening study. Magn Reson Imaging (2006) 0.87
Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study. Radiology (2006) 0.86
Quantitative analysis of dynamic contrast-enhanced MR images based on Bayesian P-splines. IEEE Trans Med Imaging (2008) 0.86
Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urol Oncol (2013) 0.84
Where are we with imaging oxygenation in human tumours? Cancer Imaging (2005) 0.81
Statistical analysis of pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. Med Image Comput Comput Assist Interv (2005) 0.81
Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: are signal intensity-time curves adequate? Breast Cancer Res Treat (2014) 0.78
Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment. J Natl Cancer Inst Monogr (2011) 0.78
Imaging breast cancer response during neoadjuvant systemic therapy. Expert Rev Anticancer Ther (2005) 0.78
Diffusion tensor imaging of the anal canal at 3 tesla: feasibility and reproducibility of anisotropy measures. J Magn Reson Imaging (2011) 0.77
Functional magnetic resonance imaging of the liver: parametric assessments beyond morphology. Magn Reson Imaging Clin N Am (2010) 0.77
Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer? Diagn Interv Radiol (2015) 0.76
Robot-assisted radical prostatectomy: Multiparametric MR imaging-directed intraoperative frozen-section analysis to reduce the rate of positive surgical margins. Radiology (2014) 0.76